Pomerantz LLP Investigates Encompass Health for Securities Fraud
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Should l Buy EHC?
Source: Globenewswire
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Encompass Health and its executives have engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
- Safety Issues Exposed: On July 15, 2025, The New York Times reported that for-profit hospitals operated by Encompass perform below average on key safety measures, particularly highlighting 34 facilities with significantly worse rates of preventable readmissions, potentially attracting regulatory scrutiny.
- Significant Stock Drop: Following the publication of the article, Encompass's stock price fell by $12.39, a decline of 10.35%, closing at $107.28, reflecting market concerns regarding the company's governance and operational safety.
- Potential Legal Action: Due to the securities fraud allegations, investors are advised to contact Pomerantz LLP, which may lead to the initiation of a class action lawsuit, thereby impacting the company's reputation and future financial performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EHC
Wall Street analysts forecast EHC stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 97.520
Low
134.00
Averages
146.75
High
160.00
Current: 97.520
Low
134.00
Averages
146.75
High
160.00
About EHC
Encompass Health Corporation is an owner and operator of inpatient rehabilitation hospitals in the United States. The Company provides compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and treatments to maximize recovery. It operates hospitals in 38 states and Puerto Rico, with concentrations in Florida and Texas. It operates approximately 166 inpatient rehabilitation hospitals. Its inpatient rehabilitation hospitals offer specialized rehabilitative care across an array of diagnoses and deliver comprehensive patient care services. It provides care to patients who suffer from cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures and a variety of debilitating neurological conditions. Its hospitals have settings for treating the debilitating effects of the COVID-19 virus, such as significant muscle weakness, cognitive impairments, shortness of breath with activity and malnutrition.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- New Hospital Announcement: Encompass Health has announced plans to build a 40-bed freestanding rehabilitation hospital in Bear, Delaware, aimed at providing high-quality rehabilitation care for patients recovering from strokes and neurological disorders, significantly enhancing access for local residents.
- Comprehensive Treatment Services: The new facility will offer 24-hour nursing care, physical, occupational, and speech therapies designed to help patients restore function and improve their quality of life, reflecting the company's commitment to addressing patient needs in rehabilitation.
- Facility Features: The hospital will include private patient rooms, a therapy gym equipped with advanced rehabilitation technologies, an activities of daily living suite, and an in-house dialysis suite, aiming to provide a holistic rehabilitation experience that enhances patient independence and quality of life.
- Market Expansion Strategy: This new hospital marks Encompass Health's second location in Delaware, further solidifying its national network of 174 rehabilitation hospitals across 39 states and Puerto Rico, demonstrating the company's ongoing commitment to growth and investment in the rehabilitation healthcare market.
See More
- New Hospital Construction: Encompass Health has announced plans to build a 40-bed freestanding rehabilitation hospital in Bear, Delaware, aimed at providing high-quality rehabilitation services for patients recovering from strokes, neurological disorders, and spinal cord injuries, which is expected to significantly enhance recovery opportunities for local patients.
- Comprehensive Treatment Services: The new hospital will offer 24-hour nursing care along with physical, occupational, and speech therapies designed to help patients restore function and improve their quality of life, reflecting the company's commitment to addressing patient needs in the rehabilitation sector.
- Facility Features: The hospital will include private patient rooms, a therapy gym equipped with advanced rehabilitation technologies, an activities of daily living suite, and an in-house dialysis suite, aiming to provide a holistic rehabilitation experience that enhances patient independence and quality of life.
- Regional Impact: This expansion will establish Encompass Health's second location in Delaware, further solidifying its leadership position in the U.S. rehabilitation hospital sector and providing greater access to rehabilitation services for residents of New Castle County and surrounding areas.
See More
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Encompass Health and its executives have engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to stock price volatility.
- Safety Issues Exposed: On July 15, 2025, The New York Times reported that for-profit hospitals operated by Encompass perform below average on key safety measures, particularly highlighting 34 facilities with significantly worse rates of preventable readmissions, potentially attracting regulatory scrutiny.
- Significant Stock Drop: Following the publication of the article, Encompass's stock price fell by $12.39, a decline of 10.35%, closing at $107.28, reflecting market concerns regarding the company's governance and operational safety.
- Potential Legal Action: Due to the securities fraud allegations, investors are advised to contact Pomerantz LLP, which may lead to the initiation of a class action lawsuit, thereby impacting the company's reputation and future financial performance.
See More
- Safety Performance Issues: According to a New York Times report, Encompass Health's for-profit hospitals are performing below average on key safety measures, with 34 facilities rated by Medicare as having statistically significantly higher rates of preventable readmissions, raising concerns about patient safety and the company's reputation.
- Fatal Errors Raise Alarm: The report highlighted several alarming mistakes leading to patient fatalities in Encompass-owned facilities, which not only raises public concerns about the quality of care but also exposes the company to potential legal liabilities and compensation claims, further impacting its financial health.
- Legal Investigation Initiated: Lowey Dannenberg P.C. is investigating whether Encompass Health has violated federal securities laws, and if confirmed, the company could face substantial fines and lawsuits, adversely affecting shareholder interests.
- Investor Loss Risk: Should investors suffer losses due to Encompass's potential violations, it may trigger class-action lawsuits, increasing uncertainty in the market and potentially impacting the company's stock performance.
See More
- Securities Fraud Investigation: Pomerantz LLP is investigating on behalf of investors of Encompass Health Corporation whether there have been securities fraud or other unlawful business practices, indicating serious concerns regarding corporate governance.
- Safety Issues Exposed: An article by The New York Times reported that for-profit hospitals operated by Encompass perform below average on key safety measures, particularly highlighting 34 facilities with statistically significantly worse rates of preventable readmissions, which may lead to decreased investor confidence.
- Significant Stock Drop: Following the publication of the report, Encompass's stock price fell by $12.39, or 10.35%, closing at $107.28 per share on July 15, 2025, reflecting market concerns over the quality of the company's operations.
- Potential Legal Consequences: Pomerantz LLP, recognized as a leading securities litigation firm, may initiate a class action lawsuit against Encompass if the investigation confirms wrongdoing, which could have significant implications for the company's future financial health and reputation.
See More

Stock Market Performance: U.S. stock indexes ended Wednesday with mixed results, with one index increasing by 0.08%.
Index Movements: Another index also rose by 0.08%, while a third index experienced a decline of 0.61%.
See More









